בדיקות רעילות בבעלי חיים

Animal toxicity tests use higher doses to predict effects of lower doses in humans, based on the quantal dose-response concept. Since testing involves fewer animals than potentially large human populations at risk, elevated doses help identify hazards that might occur at lower human exposures. This approach accounts for the statistical challenge of extrapolating from small animal samples to large populations.

LD50, or median lethal dose, is the dose lethal to half of the animal population tested. It is crucial for understanding a substance's potency and is determined using two animal species and two routes of administration, one matching expected human exposure. LD50 serves as a foundational measure for assessing toxicological risk and comparing chemical hazards.

During the 14-day post-exposure observation period, scientists monitor animals for morbidity, intoxication, lethargy, behavioral changes, and mortality. This acute phase assessment captures immediate adverse effects and helps establish safety profiles. Detailed records of these observations inform decisions about proceeding to longer-term toxicity studies.

Ninety-day repeated exposure tests involve at least three different doses and comprehensive health monitoring, including weight changes and detailed pathological examination of organs and tissues. Unlike acute studies, these tests assess effects from prolonged exposure and identify target organs. They are tailored to the route intended for human exposure and provide critical data on subchronic toxicity.

Chronic toxicity studies conducted alongside clinical trials assess carcinogenic potential, teratogenicity (congenital malformations), perinatal and postnatal toxicity, and fertility effects. These studies may last from six months to two years depending on intended human use duration. They evaluate duration-dependent effects of substances like pesticides, pharmaceutical drugs, and industrial chemicals.

Toxicity tests assume adverse effects observed in laboratory animals apply to humans after adjusting for body surface area and other physiological differences. This extrapolation is grounded on the principle that animal models can predict human hazards when dose and exposure route are appropriately matched. The process enables risk estimation for large human populations based on relatively small animal studies.

Accurate risk estimation is essential because even low incidence rates in animal studies can represent significant numbers in large human populations. For example, a 0.01% incidence of a severe effect like cancer could represent 25,000 individuals in a large population. Precise extrapolation from animal toxicity data directly impacts regulatory decisions and public safety outcomes.